Review Article

IL-33-ST2 Axis in Liver Disease: Progression and Challenge

Zijian Sun,1 Binxia Chang,2 Miaomiao Gao,1 Jiyuan Zhang,3 and Zhengsheng Zou1

1Center of Non-Infectious Liver Diseases, Peking University 302 Clinical Medical School, Beijing, China
2Center of Non-Infectious Liver Diseases, Beijing 302 Hospital, Beijing, China
3Treatment and Research Center for Infectious Diseases, Beijing 302 Hospital, Beijing, China

Correspondence should be addressed to Jiyuan Zhang; uniquezjy@163.com and Zhengsheng Zou; zszou302@163.com

Received 11 July 2017; Accepted 20 August 2017; Published 18 October 2017

Copyright © 2017 Zijian Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The new member of the IL-1 family, interleukin-33 (IL-33), participates in the progression of a variety of diseases through binding with its receptor ST2. Recently, much clinical evidence and experimental data have indicated that IL-33 is associated with various liver diseases. This review primarily addresses the relationship between IL-33 and several hepatic diseases. IL-33 can alleviate high-fat diet- (HFD-) induced hepatic steatosis and insulin resistance, and IL-33 acts as an alarmin, which quickly triggers the immune system to respond to virus invasion and toxic damage to the liver. However, when liver injury is chronic, IL-33 promotes Th2 reactions and hepatic stellate cell (HSC) activity, facilitating progression to liver fibrosis. The complicated functions of IL-33 should be considered before its clinical application.

1. Brief Introduction of IL-33

Interleukin-33 (IL-33) was originally discovered (as clone DVS 27) in a study of canine vasospastic cerebral arteries after subarachnoid haemorrhage and received attention due to its highly upregulated expression [1]. IL-33 was then identified as NF-HEV expressed in human high endothelial venules and shown to function as a nuclear factor [2]. In 2005, Schmitz and coworkers matched the sequence structure of IL-33 with the IL-1 cytokine family, and IL-33 was successfully classified as part of the IL-1 family and named IL-33. The IL-33 gene is located on chromosome 9p24.1 in humans and on the syntenic chromosome 19qC1 region in mice. IL-33 cDNA encodes 270 and 266 amino acid polypeptides in humans and mice, respectively, and the full-length proteins have respective masses of 30 and 29.9 kDa. Caspase-1 can cleave IL-33 to a mass of 18 kDa, and the amino acid similarity between human and mouse IL-33 is up to 55% [3]. IL-33 mRNA can be found in multiple cells and tissues in both humans and mice; at the protein level, IL-33 is broadly expressed in endothelial cells, epithelial cells, smooth muscle cells, and several organs, such as the lung and central nervous system [4–6].

The excellent work by Schmitz et al. indicated that IL-33 is the ligand of the orphan receptor ST2, which is a member of the IL-1 receptor family [3]. ST2 protein exists in at least 3 isoforms through diverse splicing: a transmembrane form (ST2L), a soluble form (sST2), and a novel variant [7]. ST2 is expressed by several types of haematopoietic cells [3]. In addition, ST2 is selectively and stably expressed on the surface of T helper 2 (TH2) cells but not on that of TH1 or regulatory T (Treg) cells [8, 9]. IL-33 binds ST2, which then connects with IL-1R accessory protein (IL-1RcAP) to form a heterodimeric complex [10]. sST2 is considered a decoy receptor [11] that competes with ST2L for IL-33 binding, subsequently blocking the IL-33 signalling pathway [12]. Single immunoglobulin IL-1R-related molecule (SIGIRR) associated with ST2 has the ability to inhibit IL-33/ST2-mediated signalling [13].

Binding of IL-33 with its receptor recruits myeloid differentiation primary response protein 88 (myD88), IL-1R-associated kinase 1 (IRAK1), and IRAK4 to the receptor through IL-1RacP’s Toll-interleukin 1 receptor (TIR) domain [3]. Subsequently, certain downstream signalling molecules are activated, including nuclear factor-κB (NF-κB) [14], inhibitor of NF-κB-α (IκBα), extracellular signal-regulated
kinase (ERK), p38, serine/threonine protein kinase Akt (protein kinase B), and c-Jun N-terminal kinase (JNK) [15].

Based on the conserved homeodomain-like helix-turn-helix motif in the N-terminal portion of IL-33 and on the nuclear localization signal, IL-33 may play dual roles. First, it behaves as a traditional cytokine activating downstream signalling, and second, it acts as an intracellular nuclear factor with transcriptional regulatory properties [16]. Among the numerous biological functions of IL-33, the best known is promoting polarization of naïve T cells to T H2-type immune response cells, and it can act directly on T H2 cells to increase IL-5 and IL-13 production [3]. Furthermore, IL-33 has been identified as a selective Th2 chemoattractant [17]. In addition to T H2 cells, IL-33 also interacts with many other immune cells. For example, IL-33 attenuates TLR4-induced downregulation of CXCR2 and chemotaxis in other immune cells. For example, IL-33 attenuates TLR4-induced downregulation of CXCR2 and chemotaxis in neutrophils [18], and IL-33/ST2 signalling participatates in alternatively activated M2 macrophage polarization in macrophages [19]. Another well-known function of IL-33 is that of an “alarmin”; under cell damage (necrosis) or mechanical injury conditions, active full-length IL-33 can be released rapidly to alter the immune system response [20].

IL-33 is associated with a variety of diseases. Whether IL-33 promotes or inhibits disease progression depends on the type of disease. In asthma patients, IL-33 expression was elevated significantly [5, 21], and in a mouse model of asthma, ST2+/− mice developed attenuated airway inflammation [22]. IL-33 levels were elevated in sera and synovial fluid samples of rheumatoid arthritis (RA) patients and were correlated with the activity of the disease [23]. The serum level of IL-33 decreased after anti-TNF treatment and was correlated with the production of IgM and RA-related autoantibodies [24]. IL-33 expression was significantly increased in the inflamed mucosa of inflammatory bowel disease (IBD) patients as well as in colitis mice induced by dextran sulphate sodium (DSS) [25, 26]. IL-33 expression in the brain was downregulated in Alzheimer’s disease (AD) cases compared with controls [27], and a similar conclusion was drawn by another study [28]. Recently, it has been reported that IL-33 can ameliorate AD-like pathology and cognitive decline, and the authors proposed that IL-33 is a promising potential treatment for AD [29]. As the IL-33 decoy receptor, the stST2 level rose immediately after acute myocardial infarction [30], and the serum ST2 level was identified as a novel biomarker for neurohormonal activation in heart failure patients [31]. On the other hand, researchers have found that in ischemia/reperfusion model rats, IL-33 prevented cardiomyocyte apoptosis and enhanced cardiac function through ST2 signalling [32].

2. IL-33 and Liver Disease

The relationship between IL-33 and liver disease, as well as its role in the development of liver disease, has attracted the attention of an increasing number of researchers. So far, IL-33 has been found to be involved in a variety of liver diseases, including fatty liver disease, hepatitis, liver fibrosis, and cirrhosis, along with other hepatic diseases (Table 1).

2.1. IL-33 and Fatty Liver Disease. As recently as 20 years ago, researchers realized that in many industrialized countries, nearly a quarter of adults had excessive fat accumulation in the liver, and fatty liver was a vital risk factor for serious liver disease [33]. Studies regarding the role of IL-33 in fatty liver disease have primarily focused on nonalcoholic fatty liver disease (NAFLD). The spectrum of NAFLD ranges from fatty liver alone to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis and its associated complications without a history of heavy alcohol consumption [34, 35]. NAFLD is commonly found in type 2 diabetes and obese patients, and insulin resistance is closely related to NAFLD development and prognosis [36]. One study showed that in vitro administration of IL-33 into adipose tissue cultures induced Th2 cytokine production (IL-5, IL-13, and IL-10) and downregulated the expression of adipogenic genes. Administration of IL-33 to genetically obese diabetic (ob/ob) mice resulted in reduced adiposity and improved glucose and insulin tolerance [37].

Because of the regulatory role played by IL-33 in lipid metabolism, IL-33 may have a close relationship with fatty liver. An NAFLD mouse model was successfully constructed by feeding mice with a high-fat diet (HFD) [38]. The results of a recent study showed that a HFD given to mice for 20 weeks induced upregulation of both IL-33 and ST2 mRNA and proteins. Furthermore, treatment with IL-33 alleviated HFD-induced hepatic steatosis, reduced serum alanine aminotransferase (ALT) levels, and ameliorated the expression of adipogenic genes. Administration of IL-33 to genetically obese diabetic (ob/ob) mice resulted in reduced adiposity and improved glucose and insulin tolerance [37].

2.2. IL-33 and Hepatitis. Multiple aetiological factors can lead to hepatitis, such as viral infection, alcohol abuse, toxicants, drugs, and autoimmunity. Changes in IL-33 expression in viral hepatitis and fulminant hepatitis triggered by toxins have been recently reported, suggesting that IL-33 may participate in different types of hepatitis. Approximately 70% of hepatitis C virus- (HCV-) infected patients cannot completely clear the HCV and eventually can develop persistent chronic infection. Cirrhosis and hepatocellular carcinoma can develop in many of these patients [41, 42]. What is the role of IL-33 in this disease? Wang et al. drew conclusions by comparing chronic hepatitis C (CHC) patients, spontaneously resolved HCV (SR-HCV) patients, and healthy controls (HCs). They found that serum IL-33 levels in CHC patients were significantly higher than those in HC and SR-HCV patients, while IL-33 levels decreased after treatment with interferon for 12 weeks, and this decrease was correlated with ALT and aspartate aminotransferase
### Table 1: Studies on the roles of IL-33 and ST2 in liver diseases.

| Disease                  | Result                                                                                                                                                                                                 | Ref  |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| **Fatty liver disease**  | (i) The mRNA and protein levels of both IL-33 and ST2 were increased in the mouse model of HFD-induced hepatic steatosis, and treatment with IL-33 alleviated hepatic steatosis.   | [39] |
|                         | (ii) ST2−/− mice fed with HFD exhibited increased weight gain, severe hepatic steatosis, and inflammation.                                                                                               | [40] |
|                         | (iii) The IL-33 mRNA levels in serum and liver were increased in NAFLD patients.                                                                                                                        | [39] |
|                         | (i) Serum IL-33 levels in CHC patients were significantly higher than those in HCs while decreased after treatment with interferon and were correlated with the ALT and AST concentrations. | [43, 44] |
|                         | (ii) Serum IL-33 concentrations in CHC patients were positively correlated with the levels of serum HCV RNA.                                                                                                 | [45] |
|                         | (iii) CHB patients with high serum ALT concentrations showed higher serum IL-33 and ST2 levels.                                                                                                           | [47] |
|                         | (iv) In poly(I:C)-induced murine fulminant hepatitis, the expression of IL-33 was upregulated, and in NK-depleted poly(I:C)-treated mice, liver injury was severe while NKT-deficient mice showed hepatoprotection against poly(I:C)-induced hepatitis accompanied by an increased number of IL-33-expressing hepatocytes. | [48] |
|                         | (v) IL-33-knockout mice infected by LCMV produced fewer IFN-γ+γδ T and NK cells, and rIL-33 treatment facilitated IFN-γ-producing γδ T and NK cells and inhibited IL-17+γδ T cells.           | [49, 50] |
|                         | (vi) IL-33 and ST2 levels were increased in mouse liver after Ad infection. Injection of rIL-33 resulted in a decrease in serum ALT levels and the number of Councilman bodies in the liver; meanwhile, Treg cells were upregulated and TNF-α levels in the liver decreased. | [51] |
|                         | (vii) ST2−/− mice developed severer hepatitis induced by Con A with a higher number of mononuclear cells and higher level of proinflammatory cytokines in the liver. IL-33 also suppressed caspase-3 activation and BAX expression as well as enhanced Bcl-2 expression in the liver. | [52] |
|                         | (viii) NKT-deficient mice performed resistant to Con A-induced hepatitis and lacked IL-33 expression in liver cells.                                                                                                                                                   | [53] |
|                         | (ix) IL-33 expression in hepatocytes was blocked during Con A-induced acute hepatitis in TRAIL−/−mice.                                                                                                                                                                   | [54] |
|                         | (x) The severity of liver injury in IL-33−/− mice was positively correlated with the levels of TNF-α and IL-1β and the number of NK cells infiltrating into the liver.                                                                 | [55] |
|                         | (xi) rIL-33 exacerbated Con A-induced hepatitis, while pretreatment of an IL-33-blocking antibody exhibited a protective effect.                                                                                                                                   | [56] |
| **Hepatitis**            | (i) In mouse and human fibrotic livers, IL-33 and ST2 mRNA was overexpressed and the major sources of IL-33 were HSCs.                                                                                                                                             | [60] |
|                         | (ii) IL-33 led to activation and accumulation of ILC2 through ST2 signalling in the liver, and activated ILC2 produced IL-13; then, IL-13 initiated activation and differentiation of HSCs.                                                                                  | [63] |
|                         | (iii) In ST2−/− mice with liver fibrosis, the activation of HSCs was decreased and in vitro HSCs activated by rIL-33 release IL-6, TGF-β, α-SMA, and collagen.                                                                                                           | [64] |
|                         | (iv) Serum IL-33 levels of PBC patients were positively correlated with the severity of PBC.                                                                                                                                                                           | [66] |
| **Liver fibrosis/cirrhosis** | (i) A high level of IL-33 mainly produced by CD8+ CD62L+ KLRG1− CD107α+ T cells might indicate prolonged patient survival.                                                                                                                                     | [68] |
|                         | (ii) A high level of serum sST2 is regarded as a negative HCC prognostic factor.                                                                                                                                                                                    | [69] |
|                         | (iii) IL-33 presented a significant protective effect on liver ischemia/reperfusion mouse model with attenuated liver damage and limited inflammatory activity.                                                                                                           | [72, 73] |
|                         | (iv) IL-33 participated in hepatic granuloma pathology during *Schistosoma japonicum* infection.                                                                                                                                                                      | [70] |
|                         | (v) In *Leishmania donovani*-infected liver mice, the IL-33/ST2 axis suppressed Th1 response and patients with visceral leishmaniasis showed higher serum IL-33 levels.                                                                                       | [71] |

(ALT) levels in CHC patients [43]. Meanwhile, Hamdi and coworkers obtained similar results [44]. In another study, serum HCV RNA was also detected, and it was found that serum IL-33 concentrations were positively correlated with the levels of serum HCV RNA [45].

As a pathogenic factor, IL-33 plays a role not only in CHC but also in chronic hepatitis B (CHB). Hepatitis B virus (HBV) is another major cause of chronic liver disease. After HBV infection, most adults can clear the virus spontaneously, but nearly 5% of infected adults and more than 90% of infected infants and young children will develop chronic infection [46]. CHB also has a risk of progressing to liver cirrhosis and hepatocellular carcinoma [41, 42]. One study showed that the serum IL-33 and ST2 levels were elevated as serum ALT concentrations increased in CHB patients compared to HBV carriers, HCs, and CHB patients with low ALT levels [47]. All these results suggest that IL-33 is associated with liver damage. Therefore, IL-33 has been proposed to function as an alarmin to alert the immune system of tissue damage following infection.

To facilitate research, many researchers have explored the relationship between IL-33 and hepatitis in animal hepatitis models. Arshad et al. detected IL-33 expression in murine fulminant hepatitis induced by poly(I:C), a Toll-like receptor (TLR3) viral mimetic, and by pathogenic mouse hepatitis virus (L2-MHV3). Their results showed that in both
hepatitis mouse models, the expression of IL-33 was upregulated and hepatocyte-specific IL-33 expression was downregulated in natural killer cell- (NK-) depleted poly(I:C)-treated mice with severe liver injury, while natural killer T cell- (NKT-) deficient mice exhibited hepatoprotection against poly(I:C)-induced hepatitis accompanied by an increased number of IL-33-expressing hepatocytes compared with wild-type (WT) controls [48]. Lymphocytic choriomeningitis virus- (LCMV-) infected IL-33-knockout mice were used in another study, and the study indicated that IL-33 deficiency resulted in fewer IFN-γ+ γδ T and NK cells. In contrast, recombinant IL-33 (rIL-33) facilitated IFN-γ-producing γδ T and NK cells and inhibited IL-17+ γδ T cells, revealing a role of IL-33 in regulating innate IFN-γ production and antiviral responses in LCMV-infected hepatitis [49, 50]. Liang et al. used another virus, adenovirus (Ad), to induce hepatitis. During the first week of Ad infection, a continuous increase in IL-33 and ST2 expression was observed in mouse livers. Injection of rIL-33 resulted in a decrease in serum ALT levels and the number of Councilman bodies in the liver. These changes were correlated with the upregulation of Treg cells and downregulation of macrophages, dendritic cells, and NK cells in the liver, and at the same time, TNF-α expression was inhibited by IL-33 in hepatic T cells and macrophages, and TNF-α levels in the liver decreased [51].

Another focus of the relationship between IL-33 and hepatitis is the protective role of the IL-33/ST2 axis in concanavalin A- (Con A-) induced hepatitis. A study researched by Volarevic and coworkers indicated that severe hepatitis developed in Con A-treated ST2-deficient mice, and these mice exhibited a high number of mononuclear cells in the liver and a high level of proinflammatory cytokines (TNF-α and IFN-γ). In contrast, in WT mice, the number of CD4+Foxp3+ cells was statistically higher. Furthermore, injection of IL-33 into WT mice attenuated liver damage and increased the number of liver CD4+Foxp3+ cells. IL-33 also suppressed caspase-3 activation and the expression of BAX and enhanced Bcl-2 expression in the liver [52]. Interestingly, NKT-deficient mice were also resistant to Con A-induced hepatitis and no longer expressed IL-33 in liver cells following Con A administration, while IL-33 was overexpressed in normal mice [53]. Meanwhile, IL-33 expression in hepatocytes was also blocked during Con A-induced acute hepatitis in tumour necrosis factor-related apoptosis-inducing ligand- (TRAIL-) deficient mice, and IL-33-deficient mice exhibited more severe Con A-induced liver injury than WT mice [54]. Furthermore, the severity of liver injury in IL-33−/− mice was positively correlated with TNF-α and IL-1β levels and the number of NK cells infiltrating into the liver [55]. The majority of studies in this area support the view that IL-33 protects against Con A-induced hepatitis, and this protection involves a variety of immune cells (Treg, NK, and NKT cells) and molecules (IFN-γ and TRAIL). However, the opposite result was obtained in one study: treatment of rIL-33 exacerbated Con A-induced hepatitis, but pretreatment with an IL-33-blocking antibody exhibited a protective effect, likely by suppressing the late stage of T cell and NKT cell activation and decreasing IFN-γ production [56]. More studies are needed to determine whether IL-33 protects or aggravates hepatitis induced by drugs and to elucidate the reasons for this discrepancy.

2.3. IL-33 and Liver Fibrosis (and Cirrhosis). Liver fibrosis and its end-stage form, cirrhosis, are the common final pathway for virtually all chronic liver diseases. Accumulation of extracellular matrix (ECM) rich in fibrillar collagens (mainly collagen I and collagen III) is the characteristic of advanced fibrosis, and it is associated with liver failure, portal hypertension, and a high risk of liver cancer [57, 58]. In the course of chronic hepatitis and progression to cirrhosis, in addition to persistent inflammatory infiltrate, a Th2-polarized immune response always occurs. Th1 cytokines lead to a rapid and intense inflammatory response while causing little fibrosis. In contrast, Th2 cytokines, such as IL-13, promote hepatic stellate cell (HSC) proliferation, transforming growth factor-β (TGF-β) synthesis, and fibrogenesis [59].

Based on the crucial role of Th2 cytokines in liver fibrosis formation and the pro-Th2 activity of IL-33, the relationship between IL-33 and liver fibrosis has received much attention. One study has shown that in mouse and human fibrotic livers, IL-33 and ST2 mRNA is overexpressed. Moreover, IL-33 expression was correlated with collagen expression, and the major source of IL-33 in fibrotic livers was HSCs [60]. Another study deeply explored the mechanism of IL-33 in promoting the pathogenesis of hepatic fibrosis; this mechanism involved a new type of lymphocyte, innate lymphoid cell type 2 (ILC2), which expresses IL33R-ST2. IL-33-responsive ILC2 cells are widely distributed in the mesenteric lymph nodes, spleen, and liver of mice and produce several Th2 cytokines, such as IL-4, IL-5, and IL-13 [61, 62]. The study also revealed that in hepatic fibrosis, IL-33 expression was elevated, and excess ECM deposition was sufficiently driven by IL-33 alone in the liver. Furthermore, IL-33−/− mice displayed a significant amelioration of experimental fibrosis. IL-33 led to activation and accumulation of ILC2 cells through ST2 signalling in the liver. Activated ILC2 cells produced IL-13, and then, IL-13 initiated activation and differentiation of HSCs via the IL-4Rα-STAT6 transcription factor-dependent pathway [63]. Meanwhile, another study showed that activation of HSCs was decreased in ST2-deficient liver fibrosis mice and that HSCs were activated by rIL-33 in vitro, releasing IL-6, TGF-β, α-SMA, and collagen [64].

Although earlier we introduced the idea that IL-33 could alleviate HFD-induced hepatic steatosis and insulin resistance, it has been verified that in diet-induced NASH, IL-33-mediated aggravation of hepatic fibrosis was dependent on the ST2 signalling pathway [39]. In primary biliary cirrhosis (PBC), an autoimmune liver disease with complications such as cirrhosis, liver failure, and hepatoma carcinoma [65], the serum IL-33 level of patients was positively correlated with severity [66]. In general, IL-33 showed a potential promotive effect on liver fibrosis.

There are also research teams studying the role of IL-33 in other liver diseases; for example, oncogenesis and progression of hepatocellular carcinoma (HCC) are associated with aberrant IL-33 expression [67], and upregulation of IL-33,
primarily produced by CD8⁻ CD62L⁻ KLRG1⁺ CD107a⁺ T cells, may indicate prolonged patient survival [68]. However, high levels of serum sST2 were considered a negative HCC prognostic factor [69]. During Schistosoma japonicum infection, IL-33 participated in hepatic granuloma pathology [70]; in the liver of Leishmania donovani-infected mice, the IL-33/ST2 axis suppressed Th1 response, and patients with visceral leishmaniasis exhibited higher serum IL-33 levels [71]. IL-33 exhibited a significant protective effect on a liver ischemia/reperfusion mouse model and attenuated liver damage and limited inflammatory activity [72, 73].

3. Conclusion and Expectations

It has been nearly 30 years since the discovery of IL-33, and many studies have been performed to determine the molecular structure, distribution, receptor, and signalling pathway of IL-33. Knowledge regarding the molecular basis of IL-33 signalling is relatively comprehensive. Nevertheless, the role of IL-33 is different in various liver diseases. IL-33 can attenuate hepatic steatosis and act as an alarmin by quickly triggering the immune system to respond to virus invasion and toxicant-induced damage, thus leading to a protective effect on viral hepatitis and Con A-induced liver injury. However, IL-33 promotes Th2 reactions and HSC activity, facilitating the progression to liver fibrosis. Therefore, evidence suggests that when acute and massive liver damage occurs, the release of IL-33 by injured hepatocytes might be a protective mechanism, while in chronic injury, IL-33 plays the role of a hepatic fibrosis-enhancing factor. Thus, it is necessary to judge and weigh the opposing functions of IL-33 before clinical application [74].

Although great progress has been made in understanding the relationship between IL-33 and liver disease, the majority of studies are still based on correlations between IL-33 expression and liver disease. Studies on the specific mechanism are not thorough or sufficiently comprehensive, and several experimental results suggest opposite conclusions. Hence, more studies are required to fully understand the role of IL-33 in the regulation of liver disease and its signalling pathways and regulatory networks.

Moreover, we also hope to expand the study of IL-33 to more liver diseases and find more potential therapeutic applications of IL-33. For instance, alcoholic liver disease (ALD) exhibits a disease progression similar to that of NAFLD (from simple fatty liver to alcoholic hepatitis, cirrhosis, and even HCC), and its incidence is rapidly increasing. ALD is becoming an important cause of chronic liver disease worldwide, while (except for abstinence) ALD lacks therapeutic drugs with definite efficacy [75]. Therefore, it is very likely that the role of IL-33 in ALD will be discovered and provide a new treatment approach for ALD. Further study of IL-33, a novel cytokine, could establish a new field of research on the mechanisms and treatment of liver disease.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding this article.

Authors’ Contributions

Zijian Sun and Binxia Chang participated in the design and writing of the paper; they contributed equally to the work. Jiyuan Zhang and Zhengsheng Zou participated in the design and literature review. Miaomiao Gao provided substantial advice in designing the paper.

Acknowledgments

Financial support was provided by the National Natural Science Fund of China (Grant nos. 81370530 and 81670527).

References

[1] H. Onda, H. Kasuya, K. T. Hori et al., “Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage,” Journal of Cerebral Blood Flow & Metabolism, vol. 19, no. 11, pp. 1279–1288, 1999.
[2] E. S. Baekkevold, M. Roussigné, T. Yamanaka et al., “Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules,” American Journal of Pathology, vol. 163, no. 1, pp. 69–79, 2003.
[3] J. Schmitz, A. Owyang, E. Oldham et al., “IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines,” Immunity, vol. 23, no. 5, pp. 479–490, 2005.
[4] C. Mousson, N. Ortega, and J. P. Girard, “The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?,” PLoS One, vol. 3, no. 10, article e3331, 2008.
[5] D. Prefontaine, S. Lajoie-Kadoch, S. Foley et al., “Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells,” Journal of Immunology, vol. 183, no. 8, pp. 5094–5103, 2009.
[6] C. A. Hudson, G. P. Christphi, R. C. Gruber, J. R. Wilmore, D. A. Lawrence, and P. T. Massa, “Induction of IL-33 expression and activity in central nervous system glia,” Journal of Leukocyte Biology, vol. 84, no. 3, pp. 631–643, 2008.
[7] K. Tago, T. Noda, M. Hayakawa et al., “Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V,” Biochemical and Biophysical Research Communications, vol. 285, no. 5, pp. 1377–1383, 2001.
[8] D. Xu, W. L. Chan, B. P. Leung et al., “Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells,” The Journal of Experimental Medicine, vol. 187, no. 5, pp. 787–794, 1998.
[9] S. Lecart, N. Lecointe, A. Subramaniam et al., “Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface,” European Journal of Immunology, vol. 32, no. 10, pp. 2979–2987, 2002.
[10] A. A. Chackerian, E. R. Oldham, E. E. Murphy, J. Schmitz, S. Pflanz, and R. A. Kastelein, “IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex,” Journal of Immunology, vol. 179, no. 4, pp. 2551–2555, 2007.
[11] G. Bandara, M. A. Beaven, A. Olivera, A. M. Gilfillan, and D. D. Metcalfe, “Activated mast cells produce soluble ST2, a decoy receptor for IL-33,” Journal of Allergy and Clinical Immunology, vol. 135, no. 2, article AB64, 2015.
[12] H. Hayakawa, M. Hayakawa, A. Kume, and S. Tominaga, “Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation,” The Journal of Biological Chemistry, vol. 282, no. 36, pp. 26369–26380, 2007.

[13] K. Bulek, S. Swaidani, J. Qin et al., “The essential role of single Ig IL-1 receptor-related molecule/toll IL-1R8 in regulation of Th2 immune response,” Journal of Immunology, vol. 182, no. 5, pp. 2601–2609, 2009.

[14] C. Boufi, M. Rochman, C. B. Zust et al., “IL-33 markedly activates murine eosinophils by an NF-κB-dependent mechanism differentially dependent upon an IL-4-driven autoimmune inflammatory loop,” Journal of Immunology, vol. 191, no. 8, pp. 4317–4325, 2013.

[15] C. K. Wong, K. M. Leung, H. N. Qiu, J. Y. Chow, A. O. Choi, and C. W. Lam, “Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis,” PLoS One, vol. 7, no. 1, article e29815, 2012.

[16] V. Carriere, L. Roussel, N. Ortega et al., “IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 1, pp. 282–287, 2007.

[17] M. Komai-Koma, D. Xu, Y. Li, A. N. McKenzie, I. B. McInnes, and F. Y. Liew, “IL-33 is a chemoattractant for human TH2 cells,” European Journal of Immunology, vol. 37, no. 10, pp. 2779–2786, 2007.

[18] J. C. Alves-Filho, F. Sonego, F. O. Souto et al., “Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection,” Nature Medicine, vol. 16, no. 6, pp. 708–712, 2010.

[19] M. Kurowska-Stolarska, B. Stolarski, P. Kewin et al., “IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation,” Journal of Immunology, vol. 183, no. 10, pp. 6469–6477, 2009.

[20] C. Cayrol and J. P. Girard, “IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy,” Current Opinion in Immunology, vol. 31, pp. 31–37, 2014.

[21] D. Prefontaine, J. Nadigel, F. Chouiali et al., “Increased IL-33 expression by epithelial cells in bronchial asthma,” The Journal of Allergy and Clinical Immunology, vol. 125, no. 3, pp. 752–754, 2010.

[22] M. Kurowska-Stolarska, P. Kewin, G. Murphy et al., “IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4,” Journal of Immunology, vol. 181, no. 7, pp. 4780–4790, 2008.

[23] Y. Matsuyama, H. Okazaki, H. Tamemoto et al., “Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis,” The Journal of Rheumatology, vol. 37, no. 1, pp. 18–25, 2010.

[24] R. Mu, H. Q. Huang, Y. H. Li, C. Li, H. Ye, and Z. G. Li, “Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 37, no. 10, pp. 2006–2013, 2010.

[25] J. B. Seidlin, J. T. Bjerrum, M. Coskun, B. Widjaya, B. Vainer, and O. H. Nielsen, “IL-33 is upregulated in colonocytes of ulcerative colitis,” Immunology Letters, vol. 128, no. 1, pp. 80–85, 2010.

[26] M. Sun, C. He, W. Wu et al., “Hypoxia inducible factor-1α-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease,” Clinical and Experimental Immunology, vol. 187, no. 3, pp. 428–440, 2017.

[27] J. Chapuis, D. Hot, F. Hansmann et al., “Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer’s disease,” Molecular Psychiatry, vol. 14, no. 11, pp. 1004–1016, 2009.

[28] J. T. Yu, J. H. Song, N. D. Wang et al., “Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer’s disease,” Neurobiology of Aging, vol. 33, no. 5, pp. 1014.e11–1014.e14, 2012.

[29] A. K. Fu, K. W. Hung, M. Y. Yuen et al., “IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 19, pp. E2705–E2713, 2016.

[30] M. Shimpo, D. A. Morrow, E. O. Weinberg et al., “Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction,” Circulation, vol. 109, no. 18, pp. 2186–2190, 2004.

[31] E. O. Weinberg, M. Shimpo, S. Hurwitz, S. Tominaga, J. I. Rouleau, and R. T. Lee, “Identification of serum soluble ST2 receptor as a novel heart failure biomarker,” Circulation, vol. 107, no. 5, pp. 721–726, 2003.

[32] K. Seki, S. Sanada, A. Y. Kudinova et al., “Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling,” Circulation. Heart Failure, vol. 2, no. 6, pp. 684–691, 2009.

[33] H. Z. Lin, S. Q. Yang, C. Chuckaree, F. Kuhajda, G. Ronnet, and A. M. Diehl, “Metformin reverses fatty liver disease in obese, leptin-deficient mice,” Nature Medicine, vol. 6, no. 9, pp. 998–1003, 2000.

[34] C. A. Matteoni, Z. M. Younossi, T. Gramlich, N. Boparai, Y. C. Liu, and A. J. McCullough, “Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity,” Gastroenterology, vol. 116, no. 6, pp. 1413–1419, 1999.

[35] S. Alam, G. Mustafa, M. Alam, and N. Ahmad, “Insulin resistance in development and progression of nonalcoholic fatty liver disease,” World Journal of Gastrointestinal Pathophysiology, vol. 7, no. 2, pp. 211–217, 2016.

[36] Z. M. Younossi, T. Gramlich, C. A. Matteoni, N. Boparai, and A. J. McCullough, “Nonalcoholic fatty liver disease in patients with type 2 diabetes,” Clinical Gastroenterology and Hepatology, vol. 2, no. 3, pp. 262–265, 2004.

[37] A. M. Miller, D. L. Asquith, A. J. Hueber et al., “Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice,” Circulation Research, vol. 107, no. 5, pp. 650–658, 2010.

[38] N. Pejovic, I. Jefic, N. Jovicic, N. Arsenijevic, and M. L. Lukic, “Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis,” World Journal of Gastroenterology, vol. 22, no. 44, pp. 9706–9717, 2016.

[39] Y. Gao, Y. Liu, M. Yang et al., “IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis,” Oncotarget, vol. 7, no. 23, pp. 33649–33661, 2016.

[40] N. Jovicic, I. Jefic, M. M. Kovacevic et al., “ST2 deficiency ameliorates high fat diet-induced liver steatosis in BALB/c mice,” Serbian Journal of Experimental and Clinical Research, vol. 16, no. 1, pp. 9–20, 2015.

[41] B. Rehermann and M. Nascimbeni, “Immunology of hepatitis B virus and hepatitis C virus infection,” Nature Reviews Immunology, vol. 5, no. 3, pp. 215–229, 2005.
Mediators of Inflammation

[42] S. D. Crockett and E. B. Keffe, “Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection,” *Annals of Clinical Microbiology and Antimicrobials*, vol. 4, p. 13, 2005.

[43] J. Wang, P. Zhao, H. Guo et al., “Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis C,” *Mediators of Inflammation*, vol. 2012, Article ID 819636, 7 pages, 2012.

[44] N. M. Hamdi, H. S. Al-Jurayb, H. M. Al-Nafea, R. A. Safar, K. M. Al Eisa, and N. M. Aref, “Evaluate the sustainability of viral response to antiviral treatment by IL33 assessment among hepatitis C virus Saudi patients,” *Clinical Medicine and Diagnostics*, vol. 6, no. 6, pp. 129–136, 2016.

[45] A. H. H. Wael and A. H. Mohamed, “Hepatitis C virus pathogenesis: serum IL-33 level indicates liver damage,” *African Journal of Microbiology Research*, vol. 9, no. 20, pp. 1386–1393, 2015.

[46] J. Chen and Z. Yuan, “Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies,” *Virologica Sinica*, vol. 29, no. 1, pp. 17–24, 2014.

[47] S. L. Huan, J. G. Zhao, Z. L. Wang, S. Gao, and K. Wang, “Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection,” *BMC Infectious Diseases*, vol. 16, no. 200, 2016.

[48] M. I. Arshad, S. Patrat-Delon, C. Piquet-Pellorce et al., “Pathogenic mouse hepatitis virus or poly(I:C) induce IL-33 in hepatocytes in murine models of hepatitis,” *PLoS One*, vol. 8, no. 9, article e74278, 2013.

[49] Y. J. Liang, Z. L. Jie, L. Soong, and J. Sun, “IL-33 promotes innate IFN-γ production and controls multi-functional T cell responses in viral hepatitis (IRCP.429),” *Journal of Immunology*, vol. 194, Supplement 1, p. 128.10, 2015.

[50] Y. J. Liang, Z. L. Jie, L. F. Hou et al., “IL-33 promotes innate IFN-γ production and modulates dendritic cell response in LCMV-induced hepatitis in mice,” *European Journal of Immunology*, vol. 45, no. 11, pp. 3052–3063, 2015.

[51] Y. J. Liang, Z. L. Jie, L. F. Hou et al., “IL-33 induces nuocytes and modulates liver injury in viral hepatitis,” *Journal of Immunology*, vol. 190, no. 11, pp. 5666–5675, 2013.

[52] V. Volarevic, M. Mitrovic, M. Milovanovic et al., “Protective role of IL-33/ST2 axis in Con A-induced hepatitis,” *Journal of Hepatology*, vol. 56, no. 1, pp. 26–33, 2012.

[53] M. I. Arshad, M. Rauch, A. L’Helgoualc’h et al., “NK cells are required to induce high IL-33 expression in hepatocytes during ConA-induced acute hepatitis,” *European Journal of Immunology*, vol. 41, no. 8, pp. 2341–2348, 2011.

[54] M. I. Arshad, C. Piquet-Pellorce, A. L’Helgoualc’h et al., “TRAIL but not FasL and TNFα, regulates IL-33 expression in murine hepatocytes during acute hepatitis,” *Hepatology*, vol. 56, no. 6, pp. 2353–2362, 2012.

[55] G. Noel, M. I. Arshad, A. Filliol et al., “Ablation of interaction between IL-33 and ST2 regulatory T cells increases immune cell-mediated hepatitis and activated NK cell liver infiltration,” *American Journal of Physiology Gastrointestinal and Liver Physiology*, vol. 311, no. 2, pp. G313–G323, 2016.

[56] J. Chen, L. H. Duan, A. Xiong et al., “Blockade of IL-33 ameliorates Con A-induced hepatic injury by reducing NK T cell activation and IFN-γ production in mice,” *Journal of Molecular Medicine*, vol. 90, no. 12, pp. 1505–1515, 2012.

[57] S. L. Friedman, “Liver fibrosis – from bench to bedside,” *Journal of Hepatology*, vol. 38, Supplement 1, pp. S38–S53, 2003.

[58] J. P. Iredale, “Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ,” *The Journal of Clinical Investigation*, vol. 117, no. 3, pp. 539–548, 2007.

[59] T. A. Wynn, “Fibrotic disease and the Th1/Th2 paradigm,” *Nature Reviews Immunology*, vol. 4, no. 8, pp. 583–594, 2004.

[60] P. Marvie, M. Lisbonne, A. L’Helgoualc’h et al., “Interleukin-33 overexpression is associated with liver fibrosis in mice and humans,” *Journal of Cellular and Molecular Medicine*, vol. 14, no. 6b, pp. 1726–1739, 2010.

[61] K. Moro, T. Yamada, M. Tanabe et al., “Innate production of T_{H2} cytokines by adipose tissue-associated c-Kit{^Sca-1}^ lymphoid cells,” *Nature*, vol. 463, no. 7280, pp. 540–544, 2010.

[62] A. E. Price, H. E. Liang, B. M. Sullivan et al., “Systemically dispersed innate IL-13-expressing cells in type 2 immunity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 25, pp. 11489–11494, 2010.

[63] T. McHedlidze, M. Waldner, S. Zopf et al., “Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis,” *Immunity*, vol. 39, no. 2, pp. 357–371, 2013.

[64] Z. M. Tan, Q. H. Liu, R. Q. Jiang et al., “Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells,” *Cellular & Molecular Immunology*, vol. 14, pp. 1–11, 2017.

[65] C. Selmi, C. L. Bowlus, M. E. Gershwin, and R. L. Coppel, “Primary biliary cirrhosis,” *Lancet*, vol. 377, no. 9777, pp. 1600–1609, 2011.

[66] Y. Q. Sun, J. Y. Zhang, S. Lv et al., “Interleukin-33 promotes disease progression in patients with primary biliary cirrhosis,” *The Tohoku Journal of Experimental Medicine*, vol. 234, no. 4, pp. 255–261, 2014.

[67] Y. Yang, J. B. Wang, Y. M. Li et al., “Role of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma,” *Oncology Letters*, vol. 12, no. 1, pp. 429–436, 2016.

[68] S. M. Brunner, C. Rubner, R. Kesseling et al., “Tumor-infiltrating, interleukin-33-producing effector-memory CD8{T} cells in resected hepatocellular carcinoma prolong patient survival,” *Hepatology*, vol. 61, no. 6, pp. 1957–1967, 2015.

[69] D. Bergis, V. Kassis, A. Ranglack et al., “High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma,” *Translational Oncology*, vol. 6, no. 3, pp. 311–318, 2013.

[70] H. Peng, Q. X. Zhang, X. J. Li et al., “IL-33 contributes to *Schistosoma japonicum*-induced hepatic pathology through induction of M2 macrophages,” *Scientific Reports*, vol. 6, p. 29844, 2016.

[71] O. Rostan, J. P. Gangneux, C. Piquet-Pellorce et al., “The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses TH1 responses in the livers of BALB/c mice infected with *Leishmania donovani*,” *MBio*, vol. 4, no. 5, pp. e00383–e00413, 2013.

[72] N. Sakai, H. L. Van Sweringen, R. C. Quillinn et al., “Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice,” *Hepatology*, vol. 56, no. 4, pp. 1468–1478, 2012.

[73] S. Li, F. X. Zhu, H. B. Zhang, H. Li, and Y. Z. An, “Pretreatment with interleukin-33 reduces warm hepatic ischemia/reperfusion injury in mice,” *Chinese Medical Journal*, vol. 126, no. 10, pp. 1855–1859, 2013.
[74] R. Weiskirchen and F. Tacke, “Interleukin-33 in the pathogenesis of liver fibrosis: alarming ILC2 and hepatic stellate cells,” *Cellular & Molecular Immunology*, vol. 14, no. 2, pp. 143–145, 2017.

[75] B. Gao and R. Bataller, “Alcoholic liver disease: pathogenesis and new therapeutic targets,” *Gastroenterology*, vol. 141, no. 5, pp. 1572–1585, 2011.